Biotechnology company developing vaccines for infectious diseases including COVID-19.
Novavax, Inc., a biotechnology company, is dedicated to the discovery, development, and commercialization of vaccines aimed at preventing serious infectious diseases and addressing global health needs. The company's leading vaccine candidate, NVX-CoV2373, targets the coronavirus and is undergoing extensive clinical testing, including two Phase III trials, one Phase IIb trial, and one Phase I/II trial.
Another key candidate is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine, which is in Phase 3 clinical trials. In addition, Novavax is developing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate, designed to protect against RSV infection.
Novavax's pipeline also includes an RSV F vaccine currently in Phase II clinical trials for older adults (60 years and older) and in Phase I trials for pediatric use. The company has established a collaboration agreement with Takeda Pharmaceutical Company Limited to support the development, manufacturing, and commercialization of NVX-CoV2373, its COVID-19 vaccine candidate.
Founded in 1987 and headquartered in Gaithersburg, Maryland, Novavax continues to advance its mission of providing innovative vaccines to combat infectious diseases, leveraging its proprietary nanoparticle technology to enhance vaccine efficacy and safety.